Klinisk Biokemi i Norden Nr 4, vol. 29, 2017 - page 32

32 | 
Klinisk Biokemi i Norden · 4 2017
4. Connolly SJ, Eikelboom J, Joyner C, Diener
HC, Hart R, Golitsyn S, et al. Apixaban in
patients with atrial fibrillation. N Engl J Med
2011;364:806-817.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy
SA, Wiviott SD, Halperin JL, et al. Edoxaban
versus warfarin in patients with atrial fibrilla-
tion. N Engl J Med 2013;369:2093-2104.
6. Sjögren V, Byström B, Renlund H, Svens-
son PJ, Oldgren J, Norrving B, Själander A.
Non-vitamin K oral anticoagulants are non-
inferior for stroke prevention but cause fewer
major bleedings than well-managed warfa-
rin: A retrospective register study. PLoS One
2017;12:e0181000.
7. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf
S, Eikelboom JW, et al. The effect of dabigatran
plasma concentrations and patient characte-
ristics on the frequency of ischemic stroke and
major bleeding in atrial fibrillation patients:
the RE-LY Trial (Randomized Evaluation of
Long-Term Anticoagulation Therapy). J Am
Coll Cardiol 2014;63:321-328.
8. Ruff CT, Giugliano RP, Braunwald E, Morrow
DA, Murphy SA, Kuder JF, et al. Association
between edoxaban dose, concentration, anti-
Factor Xa activity, and outcomes: an ana-
lysis of data from the randomised, double-
blind ENGAGE AF-TIMI 48 trial. Lancet
2015;385:2288-2295.
9. Baglin T. The role of the laboratory in treat-
ment with new oral anticoagulants. J Thromb
Haemost 2013;11 Suppl 1:122-128.
10. Lindahl TL, Baghaei F, Blixter IF, Gustafsson
KM, Stigendal L, Sten-Linder M, et al. Effects
of the oral, direct thrombin inhibitor dabi-
gatran on five common coagulation assays.
Thromb Haemost 2011;105:371-378.
11. Hillarp A, Baghaei F, Fagerberg Blixter I, Gus-
tafsson KM, Stigendal L, Sten-Linder M, et al.
Effects of the oral, direct factor Xa inhibitor
rivaroxaban on commonly used coagulation
assays. J Thromb Haemost 2011;9:133-139.
12. Hillarp A, Gustafsson KM, Faxälv L, Strand-
berg K, Baghaei F, Fagerberg Blixter I, et al.
Effects of the oral, direct factor Xa inhibi-
tor apixaban on routine coagulation assays
and anti-FXa assays. J Thromb Haemost
2014;12:1545-1553.
13. Douxfils J, Chatelain B, Chatelain C, Dogne
JM, Mullier F. Edoxaban: Impact on rou-
tine and specific coagulation assays. A prac-
tical laboratory guide. Thromb Haemost
2016;115:368-381.
14. Antovic A, Norberg EM, Berndtsson M, Ras-
muson A, Malmström RE, Skeppholm M,
Antovic J. Effects of direct oral anticoagulants
on lupus anticoagulant assays in a real-life
setting. Thromb Haemost 2017;117:1700-4.
15. Sennesael AL, Exner T, Chatelain B, Lessire
S, Larock AS, Vancraeynest C, et al. An opti-
mized dRVVT-based assay to estimate the
intensity of anticoagulation in patients treated
with direct oral anticoagulants. Thromb Res
2017;157:29-37.
16. Letertre LR, Gudmundsdottir BR, Francis
CW, Gosselin RC, SkeppholmM, Malmstrom
RE, et al. A single test to assay warfarin, dabi-
gatran, rivaroxaban, apixaban, unfractionated
heparin, and enoxaparin in plasma. J Thromb
Haemost 2016;14:1043-1053.
17. Onundarson PT, Francis CW, Indridason OS,
Arnar DO, Bjornsson ES, Magnusson MK, et
al. Fiix-prothrombin time versus standard
prothrombin time for monitoring of warfarin
anticoagulation: a single centre, double-blind,
randomised, non-inferiority trial. Lancet Hae-
matol 2015;2:e231-240.
18. Tomas L. Lindahl, Kerstin Arbring, Maria
Wallstedt & Mats Rånby (2017): A novel
prothrombin time method to measure all
non-vitamin K-dependent oral anticoagulants
(NOACs), Upsala Journal of Medical Sciences,
DOI: 10.1080/03009734.2017.1370040
19. Samuelson BT, Cuker A, Siegal DM, Crowther
M, Garcia DA. Laboratory assessment of
the anticoagulant activity of direct oral
anticoagulants: a systematic review. Chest
2017;151:127-138.
20. Dale BJ, Chan NC, Eikelboom JW. Laboratory
measurement of the direct oral anticoagu-
lants. Br J Haematol 2016;172:315-336.
1...,22,23,24,25,26,27,28,29,30,31 33,34,35,36,37,38,39,40,41,42,...52
Powered by FlippingBook